Galantamine is an allosterically potentiating ligand of the human α4/β2 nACHR

Acta Neurologica Scandinavica, Supplement

Volumn 102, Issue 176, 2000, Pages 68-73

  Samochocki, M ^a   Zerlin, M ^a   Jostock, R ^a   Groot Kormelink, P J ^b   Luyten, W H M L ^b   Albuquerque, E X ^c   Maelicke, A ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b JANSSEN RESEARCH FOUNDATION   (Belgium)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

4 2 nAChR; AChE inhibitor; Alzheimer; APL; Galantamine; Human nAChR; Reminyl

Indexed keywords

ACETYLCHOLINESTERASE; CHOLINERGIC RECEPTOR; CHOLINERGIC RECEPTOR ALPHA4; CHOLINERGIC RECEPTOR BETA2; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; METRIFONATE; RECEPTOR SUBUNIT; RIVASTIGMINE; SABELUZOLE; TACRINE; UNCLASSIFIED DRUG; LIGAND; NICOTINIC RECEPTOR;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; CELL LINE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG RECEPTOR BINDING; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; KIDNEY CELL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION; ANIMAL; BRAIN; DOSE RESPONSE; DRUG EFFECT; MOUSE; PHYSIOLOGY;

ALLOSTERIC REGULATION; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GALANTAMINE; HUMANS; LIGANDS; MICE; RECEPTORS, NICOTINIC;

EID: 0034569152     PISSN: 00651427     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Cholinesterase inhibitors: From the Calabar bean to Alzheimer therapy
2. Enhancement of memory by physostigmine in Alzheimer's disease
3. Cholinergic underactivity in human memory disorders
4. Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease
5. Nicotinic acetylcholine binding sites in Alzheimer's disease
6. 3H) acetylcholine binding sites in the frontal cortex of Alzheimer brains
7. Nicotinic cholinoreceptive neurons of the frontal cortex are reduced in Alzheimer's disease
8. Alteration in nicotine binding sites in Parkinson's disease, Lewy Body Dementia and Alzheimer's disease, possible index of early neuropathology
9. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer brains: In vivo assessment using positron emission tomography
10. Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease - Histotopographical correlation with amyloid plaques and hyperphosphorylated tau-protein
11. α4 but not β3 and α7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease
12. Nicotinic receptor activation in human cerebral cortical interneurons: A mechanism for inhibition and disinhibition of neuronal networks
13. Stable expression in HEK-293 cells of the rat α3/β4 subtype of neuronal nicotinic acetylcholine receptor
14. Cloning and sequence of full-length cDNAs encoding the human neuronal nicotinic receptor (nAChR) subunits β3 and β4 and expression of seven nAChR subunits in the human neuroblastoma cell line SH-SY5Y and/or IMR-32
15. A second pathway of activation of the Torpedo acetylcholine receptor channel
16. Physostigmine and galantamine: Probes for a novel binding site on the α4β2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells
17. Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system
18. Agonist responses of neuronal nicotinic receptors are potentiated by a novel class of allosterically acting ligands
19. Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons
20. Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine
21. Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor α-polypeptide
22. New approach to drug therapy of Alzheimer's dementia
23. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
24. Biochemical aspects of cholinergic excitation
25. Nicotinic receptor: An allosteric protein specialized for intercellular communication
26. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease
27. Physo-stigmine, galantamine and codeine act as non-competitive nicotinic agonists on clonal rat pheochromocytoma cells
28. Cholinesterase inhibitors in the treatment of Alzheimer's disease: A comparison of tolerability and pharmacology
29. A 24-week randomized trial of controlled-release physostig- mine in patients with Alzheimer's disease
30. Galantamine (Reminyl™) in the treatment of mild to moderate Alzheimer's disease. Clinical expert report
31. Choline is a selective agonist of α7 nicotinic acetylcholine receptors
32. Nicotinic acetylcholine involvement in cognitive function in animals
33. Choline and selective antagonists identify two subtypes of nicotinic acetylcholine receptors that modulate GABA release from CAl interneurons in rat hippocampal slices
34. Chronic nicotine treatment upregulates α3 AChRs and α7 AChRs expressed by the human neuroblastoma cell line SH-SY5Y
35. CNS nicotine receptors. Possible therapeutic targets in neurodegenerative disorders
36. Stimulation of alpha4beta2 nicotinic acetylcholine receptors inhibits beta-amyloid toxicity